Cargando…
Coronary atherosclerosis and chemotherapy: From bench to bedside
Cardiovascular disease, particularly coronary artery disease, is the leading cause of death in humans worldwide. Coronary heart disease caused by chemotherapy affects the prognosis and survival of patients with tumors. The most effective chemotherapeutic drugs for cancer include proteasome inhibitor...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892653/ https://www.ncbi.nlm.nih.gov/pubmed/36742069 http://dx.doi.org/10.3389/fcvm.2023.1118002 |
_version_ | 1784881367341858816 |
---|---|
author | Zhou, Fanghui Zhu, Xinxin Liu, Yao Sun, Yue Zhang, Ying Cheng, Dechun Wang, Wei |
author_facet | Zhou, Fanghui Zhu, Xinxin Liu, Yao Sun, Yue Zhang, Ying Cheng, Dechun Wang, Wei |
author_sort | Zhou, Fanghui |
collection | PubMed |
description | Cardiovascular disease, particularly coronary artery disease, is the leading cause of death in humans worldwide. Coronary heart disease caused by chemotherapy affects the prognosis and survival of patients with tumors. The most effective chemotherapeutic drugs for cancer include proteasome inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, 5-fluorouracil, and anthracyclines. Animal models and clinical trials have consistently shown that chemotherapy is closely associated with coronary events and can cause serious adverse cardiovascular events. Adverse cardiovascular events after chemotherapy can affect the clinical outcome, treatment, and prognosis of patients with tumors. In recent years, with the development of new chemotherapeutic drugs, new discoveries have been made about the effects of drugs used for chemotherapy on cardiovascular disease and its related mechanisms, such as inflammation. This review article summarizes the effects of chemotherapeutic drugs on coronary artery disease and its related mechanisms to guide efforts in reducing cardiovascular adverse events during tumor chemotherapy, preventing the development of coronary heart disease, and designing new prevention and treatment strategies for cardiotoxicity caused by clinical tumor chemotherapy. |
format | Online Article Text |
id | pubmed-9892653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98926532023-02-03 Coronary atherosclerosis and chemotherapy: From bench to bedside Zhou, Fanghui Zhu, Xinxin Liu, Yao Sun, Yue Zhang, Ying Cheng, Dechun Wang, Wei Front Cardiovasc Med Cardiovascular Medicine Cardiovascular disease, particularly coronary artery disease, is the leading cause of death in humans worldwide. Coronary heart disease caused by chemotherapy affects the prognosis and survival of patients with tumors. The most effective chemotherapeutic drugs for cancer include proteasome inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, 5-fluorouracil, and anthracyclines. Animal models and clinical trials have consistently shown that chemotherapy is closely associated with coronary events and can cause serious adverse cardiovascular events. Adverse cardiovascular events after chemotherapy can affect the clinical outcome, treatment, and prognosis of patients with tumors. In recent years, with the development of new chemotherapeutic drugs, new discoveries have been made about the effects of drugs used for chemotherapy on cardiovascular disease and its related mechanisms, such as inflammation. This review article summarizes the effects of chemotherapeutic drugs on coronary artery disease and its related mechanisms to guide efforts in reducing cardiovascular adverse events during tumor chemotherapy, preventing the development of coronary heart disease, and designing new prevention and treatment strategies for cardiotoxicity caused by clinical tumor chemotherapy. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9892653/ /pubmed/36742069 http://dx.doi.org/10.3389/fcvm.2023.1118002 Text en Copyright © 2023 Zhou, Zhu, Liu, Sun, Zhang, Cheng and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Zhou, Fanghui Zhu, Xinxin Liu, Yao Sun, Yue Zhang, Ying Cheng, Dechun Wang, Wei Coronary atherosclerosis and chemotherapy: From bench to bedside |
title | Coronary atherosclerosis and chemotherapy: From bench to bedside |
title_full | Coronary atherosclerosis and chemotherapy: From bench to bedside |
title_fullStr | Coronary atherosclerosis and chemotherapy: From bench to bedside |
title_full_unstemmed | Coronary atherosclerosis and chemotherapy: From bench to bedside |
title_short | Coronary atherosclerosis and chemotherapy: From bench to bedside |
title_sort | coronary atherosclerosis and chemotherapy: from bench to bedside |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892653/ https://www.ncbi.nlm.nih.gov/pubmed/36742069 http://dx.doi.org/10.3389/fcvm.2023.1118002 |
work_keys_str_mv | AT zhoufanghui coronaryatherosclerosisandchemotherapyfrombenchtobedside AT zhuxinxin coronaryatherosclerosisandchemotherapyfrombenchtobedside AT liuyao coronaryatherosclerosisandchemotherapyfrombenchtobedside AT sunyue coronaryatherosclerosisandchemotherapyfrombenchtobedside AT zhangying coronaryatherosclerosisandchemotherapyfrombenchtobedside AT chengdechun coronaryatherosclerosisandchemotherapyfrombenchtobedside AT wangwei coronaryatherosclerosisandchemotherapyfrombenchtobedside |